Detalhe da pesquisa
1.
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance.
J Antimicrob Chemother
; 79(2): 339-348, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153241
2.
Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.
Open Forum Infect Dis
; 6(4): ofz142, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968060
3.
Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor-Sparing Antiretroviral Therapy in a High-HBV Endemicity Setting.
Open Forum Infect Dis
; 5(10): ofy251, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30377627